Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering.
Global Oligonucleotide Therapeutics Market to Reach USD 72.1 Billion by 2035 at a 23.4% CAGR
The global oligonucleotide therapeutics market was valued at USD 7.7 billion in 2025 and is projected to reach USD 72.1 billion by 2035, expanding at a compound annual growth rate of 23.4%. Strong clinical progress, increasing regulatory approvals, advanced RNA drug delivery technologies, and expanding applications across chronic, metabolic, neurological, and rare genetic diseases are expected to support sustained market growth.
Oligonucleotide therapeutics are moving beyond their initial concentration in rare diseases and becoming an increasingly established category across the global biopharmaceutical industry. Advances in RNA-based medicine, conjugation chemistries, molecular design, and targeted delivery are improving treatment stability, efficacy, durability, and dosing convenience. These developments are strengthening clinical adoption while enabling manufacturers to address larger patient populations and a broader range of therapeutic indications.
Rising investment in biopharmaceutical research and development is also accelerating pipeline expansion. Pharmaceutical and biotechnology companies are advancing next-generation RNA platforms designed to improve therapeutic precision, extend dosing intervals, and simplify administration. Strategic collaborations among drug developers, academic institutions, research organizations, and technology providers are helping shorten development timelines and expand access to specialized scientific capabilities.
Antisense oligonucleotides accounted for 39.9% of the global oligonucleotide therapeutics market in 2025. The segment's leading position reflects its established clinical utility, growing regulatory validation, and application across multiple disease areas. Continued innovation in sequence design, chemistry, formulation, and delivery systems is expected to reinforce the clinical and commercial importance of antisense oligonucleotide therapies throughout the forecast period.
By route of administration, the subcutaneous segment represented 56.4% of the market in 2025. Subcutaneous administration supports self-administration, reduces dependence on clinical facilities, and can improve adherence to long-term treatment regimens. The growing availability of long-acting formulations and extended dosing schedules is expected to further strengthen demand for subcutaneously administered RNA-based therapeutics.
North America led the global oligonucleotide therapeutics market with a 57.9% share in 2025. The region's dominance is supported by extensive biopharmaceutical innovation, advanced healthcare infrastructure, substantial research funding, favorable reimbursement frameworks, and early adoption of RNA-targeted therapies. A well-established regulatory environment, significant investment in rare disease research, and strong commercial uptake of high-value treatments are also contributing to regional growth.
Leading companies operating in the global oligonucleotide therapeutics market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics, Biogen, Astellas Pharma, Novartis, AstraZeneca, Novo Nordisk, Sanofi, Arrowhead Pharmaceuticals, and NS Pharma. These companies are investing in proprietary RNA platforms, precision medicine strategies, advanced delivery systems, and scalable manufacturing capabilities to improve product performance and support future commercial demand.
Competitive strategies increasingly include pipeline diversification, licensing agreements, research partnerships, acquisitions, and manufacturing expansion. Market participants are also prioritizing formulation improvements that enhance stability, efficacy, product quality, and patient compliance. As clinical evidence continues to expand and RNA-targeted medicines enter additional therapeutic categories, competition is expected to intensify across discovery, development, production, and commercialization.
Comprehensive Market Analysis and Forecast
The outlook for the global oligonucleotide therapeutics market remains highly favorable as scientific innovation, clinical validation, and commercial investment converge. Broader disease applications, more efficient delivery technologies, patient-friendly administration formats, and stronger manufacturing capacity are expected to position oligonucleotide therapeutics as an important long-term growth area within the global pharmaceutical market.
Key Attributes:
Key Topics Covered:
Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research approach
1.3 Quality commitments
1.3.1 GMI AI policy & data integrity commitment
1.3.1.1 Source consistency protocol
1.4 Research trail & confidence scoring
1.4.1 Research trail components
1.4.2 Scoring components
1.5 Data collection
1.5.1 Partial list of primary sources
1.6 Data mining sources
1.6.1 Paid sources
1.6.1.1 Sources, by region
1.7 Base estimates and calculations
1.7.1 Base year calculation for any one approach
1.8 Forecast model
1.8.1 Quantified market impact analysis
1.8.1.1 Mathematical impact of growth parameters on forecast
1.9 Research transparency addendum
1.9.1 Source attribution framework
1.9.2 Quality assurance metrics
1.9.3 Our commitment to trust
Chapter 2 Executive Summary
2.1 Industry 360 synopsis
2.2 Key market trends
2.2.1 Regional trends
2.2.2 Molecule type trends
2.2.3 Indication trends
2.2.4 Route of administration trends
2.2.5 End use trends
2.3 CXO perspectives: Strategic imperatives
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing approvals of novel oligonucleotide therapeutics across multiple disease indications
3.2.1.2 Rising prevalence and improved diagnosis of rare genetic disorders
3.2.1.3 Strong regulatory support through orphan drug designation and expedited approval pathways
3.2.2 Industry pitfalls and challenges
3.2.2.1 High treatment costs and reimbursement challenges
3.2.2.2 Complex manufacturing processes and stringent quality requirements
3.2.2.3 Limited applicability beyond specific genetic or molecular targets
3.2.3 Market opportunities
3.2.3.1 Expansion of oligonucleotide therapeutics into high-prevalence chronic diseases such as cardiovascular, metabolic, and neurodegenerative disorders
3.2.3.2 Growing investment in next-generation delivery platforms and tissue-targeted oligonucleotide technologies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 North America
3.4.2 Europe
3.4.3 Asia-Pacific
3.4.4 Latin America
3.4.5 Middle East and Africa
3.5 Technology and innovation landscape
3.5.1 Current technological trends
3.5.2 Emerging technologies
3.6 Pricing analysis (Driven by Primary Research)
3.6.1 Historical price trend analysis
3.6.2 Pricing analysis, by molecule type
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Investment & funding analysis
3.10 Pipeline and clinical trial landscape
3.11 Future market trends
3.12 Impact of AI & Generative AI on the market
Chapter 4 Competitive Landscape, 2025
4.1 Introduction
4.2 Company market share analysis
4.2.1 North America
4.2.2 Europe
4.2.3 Asia-Pacific
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Merger and acquisition
4.6.2 Partnership and collaboration
4.6.3 New product launches
4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, by Molecule Type, 2022-2035 ($ Mn)
5.1 Key trends
5.2 Antisense oligonucleotides (ASOs)
5.3 Small interfering RNA (siRNA)
5.4 Aptamers
Chapter 6 Market Estimates and Forecast, by Indication, 2022-2035 ($ Mn)
6.1 Key trends
6.2 Neurology & neuromuscular diseases
6.3 Rare hereditary & metabolic diseases
6.4 Cardiovascular & lipid disorders
6.5 Hematological disorders
6.6 Ophthalmology
6.7 Other therapeutic areas
Chapter 7 Market Estimates and Forecast, by Route of Administration, 2022-2035 ($ Mn)
7.1 Key trends
7.2 Subcutaneous
7.3 Intravenous
7.4 Intrathecal
7.5 Intravitreal
Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics & ambulatory care
8.4 Home care settings
8.5 Research institutes & academic medical centers
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia-Pacific
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles
10.1 Alnylam Pharmaceuticals
10.2 Arrowhead Pharmaceuticals
10.3 Astellas Pharma
10.4 AstraZeneca
10.5 Biogen
10.6 Ionis Pharmaceuticals
10.7 Novartis
10.8 NS Pharma
10.9 Novo Nordisk
10.10 Sarepta Therapeutics
10.11 Sanofi
For more information about this report visit https://www.researchandmarkets.com/r/tmirh4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.